Gene · 10
Papers3,552
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,552
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Understanding antituberculosis drug-induced hepatotoxicity: Risk factors and effective management strategies in the pediatric population. | World J Clin Pediatr | 2025 | 40491731 | PubTator, text mining | PubMed |
| Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population. | Front Pharmacol | 2025 | 40376268 | PubTator, text mining | PubMed |
| NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort. | Int J Mol Sci | 2025 | 40332508 | PubTator, text mining | PubMed |
| Optimized Sampling Strategies for Isoniazid in East Asian Pediatric Populations Using Population Pharmacokinetics-Informed Approaches. | Drug Des Devel Ther | 2025 | 40330817 | PubTator, text mining | PubMed |
| Pharmacogenomics and Pharmacokinetics of Aspirin in Preeclampsia Prevention. | Circ Res | 2025 | 40329906 | PubTator, text mining | PubMed |
| Xenobiotic metabolizing gene variants and the risk of male infertility - A systematic review, meta-analysis and in silico analysis. | Toxicol Rep | 2025 | 40271533 | PubTator, text mining | PubMed |
| Metabolism and genotoxicity of 4,4'-oxydianiline is dependent on N-acetyltransferase 2 genetic polymorphism. | Environ Toxicol Pharmacol | 2025 | 40246217 | PubTator, text mining | PubMed |
| Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial. | J Infect Dis | 2025 | 40239986 | PubTator, text mining | PubMed |
| Allele-specific detection of isoniazid metabolism modulating variants of N-acetyltransferase 2 enzyme and their frequencies in the Bangladeshi population. | Gene | 2025 | 40204038 | PubTator, text mining | PubMed |
| Opportunities and Challenges of Population Pharmacogenomics. | Ann Hum Genet | 2025 | 40171627 | PubTator, text mining | PubMed |
| Comprehensive pharmacogenomics profiling of the Serbian population. | Front Pharmacol | 2025 | 40166472 | PubTator, text mining | PubMed |
| One-year mortality of tuberculosis patients on isoniazid-based treatment and its association with rapid acetylator NAT2 genotypes. | Int J Infect Dis | 2025 | 40147587 | PubTator, text mining | PubMed |
| Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review. | Ann Med | 2025 | 40138446 | PubTator, text mining | PubMed |
| Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential. | Sci Rep | 2025 | 40133601 | PubTator, text mining | PubMed |
| NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors. | Biochim Biophys Acta Mol Basis Dis | 2025 | 40081304 | PubTator, text mining | PubMed |
| A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling. | CPT Pharmacometrics Syst Pharmacol | 2025 | 40067154 | PubTator, text mining | PubMed |
| Impact of Genetic Variants on Pregabalin Pharmacokinetics and Safety. | Pharmaceuticals (Basel) | 2025 | 40005966 | PubTator, text mining | PubMed |
| Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis. | Pharmacogenet Genomics | 2025 | 39960813 | PubTator, text mining | PubMed |
| Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence. | Int J Clin Pharm | 2025 | 39954223 | PubTator, text mining | PubMed |
| Correction to: NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study. | Clin Infect Dis | 2025 | 39903651 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10/papers?page=5